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Abstract - Transmitted drug resistance (TDR) is one of the consequences of the high variability of HIV-1. The widespread 
use of antiretroviral therapy for the treatment of HIV-1 infection results in a large circulating pool of resistant virus vari-
ants. It is known that TDR mutations can persist for extended periods and may pose an important problem to the overall 
success of antiretroviral therapy. Factors that determine the duration of continuous persistence of resistance-associated 
mutations are the number and type of these mutations and their impact on viral fitness. Here we describe the follow-up 
of a case study of prolonged persistence of resistance-associated mutations, namely RT mutations Q151M, K65KR and 
Y181C conferring an intermediate-to-high level resistance to multiple NRTIs and NNRTIs that lasted for seven years. The 
infection was caused by subtype G virus.
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INTRODUCTION
Transmitted drug resistance (TDR) is one of the 
consequences of the high variability of human im-
munodeficiency  virus  type  1  (HIV-1)  (Martinez-
Picado and Martinez, 2008; Sanabani et al., 2011). 
The main characteristics of this RNA virus are its 
enormous genetic variability (3 x 10-5 mutations per 
nucleotide  per  replication  cycle)  (Mansky,  1996) 
and rapid turnover in vivo (10.3x109 particles per 
day) (Perelson et al., 1996). The widespread use of 
antiretroviral therapy for the treatment of HIV-1 
infection results in a large circulating pool of resist-
ant virus variants (Vandamme et al., 2011; Wittkop 
et al., 2011). Another consequence of the genetic di-
versity of HIV-1 is the existence several genetically 
distinct groups (M, N, O, P). In particular, within 
the M group a number of pure subtypes (A to K) 
and circulating recombinant forms exist, with dif-
fering geographical representation (Hemelaar et al., 
2011). 
The three main antiretroviral drug classes in use, 
nucleoside reverse-transcriptase inhibitors (NRTIs), 
non-NRTIs (NNRTIs) and protease inhibitors (PIs), 
are the main causes of TDR (Chan and Kantor, 2009). 
Highly active antiretroviral therapy (HAART), based 
on  a  combination  of  three  or  more  antiretroviral 
drugs (ARV), was initiated in 1996. The main aim 
of this therapy was to suppress the plasma viral load 
to undetectable levels, i.e. <50 copy HIV RNA/ml 
plasma (Ceccherini-Silberstein et al., 2010). Imple-
mentation of HAART has significantly improved life 
quality and reduced morbidity and mortality of HIV 
infected patients in the last decades (Gallego et al., 
2003; Lemey et al., 2005; Jakobsen et al., 2010). On 
the other hand, long-term use of this therapy has 
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of  drug  resistance-associated  mutations  assumes 
central place (Nijhuis et al., 2001). 
Considering  the  aforementioned,  the  number 
of studies related to the subject of transmitted drug 
resistance has constantly grown in the past decade 
(van de Vijver et al., 2006; Sagir et al., 2007; Smith et 
al., 2007; Wittkop et al., 2011). The results of these 
studies indicate that the overall prevalence of TDR 
was increasing in developed countries until a few 
years ago. Recent data appoints to the stabilization 
of the number of patients infected with HIV-1 re-
sistant strains. According to data from the SPREAD 
program, covering the period from September 2002 
through December 2005, the overall prevalence of 
TDR was 8.4% in Europe (Vercauteren et al., 2009). 
These results are similar to those published in pre-
vious reports of SPREAD program (during 1996-
2002, 10.4% and 2002-2003, 9.1%) (Wensing et al., 
2005;  SPREAD  program  AIDS,  2008),  as  well  as 
other studies (van de Vijver et al., 2006; Sagir et al., 
2007; Smith et al., 2007; Wittkop et al., 2011). Exist-
ing data obtained over a period of 10 years have con-
firmed the stabilization in the number of patients 
who are infected with resistant strains. Moreover, 
several studies indicate that some risk behaviors, 
such as men who have sex with men (MSM), are 
related to the higher prevalence of TDR (Weinstock 
et al., 2004).
The  transmission  of  drug-resistant  viruses  has 
been  revealed  to  occur  through  several  different 
routes, including heterosexual and homosexual in-
tercourse, intravenous drug use and vertically, from 
mother to child (Erice et al., 1993; Veenstra et al., 
1995; Boden et al., 1999). Potential sources for the 
transmission of primary resistance are people who 
do not know their infection status, patients who do 
not use antiretroviral therapy because of a high CD4 
cell count and patients with HAART failure. 
The most widely used markers of primary re-
sistance  are  Surveillance  Drug  Resistance  Muta-
tions (SDRM). In 2007, the list of SDRMs was estab-
lished by the World Health Organization (WHO), 
and expanded further in 2009, as a result of both 
the emergence of new antiretroviral drugs and new-
ly recognized resistance mutations (Bennett et al., 
2009).
Within the survey of primary resistance in Serbia 
as part of the SPREAD program since 2002, multi-
ple cases of resistance mutations have been revealed, 
among others a case of transmission of the multid-
rug resistance (MDR) thymidine analog mutations 
(TAMs) complex mutation Q151M. Here we describe 
the follow-up of this case, which is characterized by 
the persistence of primary resistance for seven years, 
prior to therapy initiation. 
MATERIALS AND METHODS
Clinical and epidemiological data were collected 
with informed patient consent. Genotypic resist-
ance testing was done on a sample taken upon diag-
nosis of HIV infection, and repeated subsequently, 
using an in-house genotypic resistance assay. HIV 
RNA extraction was done from 500 μl blood plas-
ma (kept at -80˚C). After centrifugation, 220 μl of 
plasma was removed; the rest was used for RNA 
extraction with the QIAamp Viral RNA Mini Kit 
(Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. Extracted RNA was reverse-
transcribed and amplified by the nested RT-PCR 
protocol, using a One Step RNA PCR Kit (Qiagen, 
Hilden, Germany) for the outer reaction and a Taq 
PCR Core Kit (Qiagen, Hilden, Germany) for inner 
PCR reaction. The outer primer pair, HIV_AV159 
and HIV_AV192, was used first. Nested reactions 
were performed with the primer pair HIV_AV190 
and HIV_AV 191 (Table 1) (Snoeck et al., 2005). 
The obtained product was sequenced by dye-termi-
nator sequencing on an ABI 310 automated DNA 
sequencer  (Applied  Biosystem,  Foster  City,  CA, 
USA), using seven different primers (HIV_AV36, 
HIV_AV191, HIV_AV75, HIV_RVP3, HIV_AV22, 
HIV_AV44, HIV_AV190) (Table 1.). The obtained 
sequence was examined for mutations in the re-
verse transcriptase (RT) and protease (PR) gene 
using the algorithm provided by the HIV Drug Re-
sistance  Database  (available  at  http://hivdb.stan-
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RESULTS
A 21 year-old female patient (patient A) was diag-
nosed as HIV positive in August 2003 at the Center 
for HIV/AIDS, Belgrade. Her HIV status was discov-
ered after an episode of lymphadenopathy and fever. 
At the time of inclusion in the study, the patient was 
in the CDC stage A. The plasma HIV-1 RNA levels 
and CD4 cell counts were 482/mm3 and 1000 c/ml, 
respectively. Genotypic resistance testing upon HIV 
infection diagnosis revealed the presence of primary 
resistance  mutations.  It  contained  Q151M,  K65R, 
Y181C and other PI and RT mutations and polymor-
phisms (Table 2.). Detailed sequence analysis also 
revealed the subtype G of HIV-1.
  Patient A was infected from a known source 
who is on ARV therapy. The source patient (patient 
B) was diagnosed in June 2002 and immediately be-
gan anti-TB therapy for disseminated tuberculosis. 
ARV therapy, including abacavir (ABC), lamivudine 
(3TC) and stavudine (d4T) was also initiated (Fig 
1.). Five months later, in November 2002, due to vi-
rologic failure the therapy was switched to abacavir 
(ABC),  didanosine  (ddI)  and  lamivudine  (3TC). 
Initial genotypic testing revealed that patient B’s pre-
treatment sample was not associated with drug re-
sistance mutations; however, an identical pattern of 
mutations was found in the on-treatment sample of 
the same patient and the recipient sample. 
Subsequently, patient A was followed-up for sev-
eral years; her clinical status did not progress signifi-
cantly, with the CD4 cell count always >350/ml and 
pVL constantly in the range of log3. Periodical geno-
typic-resistance testing (Fig 1.) revealed the continu-
ous presence of previously detected resistance muta-
tions. In this case, the persistence of RT mutations 
Q151M, K65R and Y181C lasted for over seven years. 
In June 2010, the patient became pregnant, with CD4 
431/ml, pVL 1702 c/ml and still detectable primary 
resistance mutations, seven years after diagnosis. The 
patient was not on an antiretroviral regime until the 
second trimester of pregnancy. Antiretroviral ther-
apy was initiated in the second trimester consisting 
of lopinavir/ritonavir (LPN/RTN), saquinavir (SQV) 
and lamivudine (3TC), which led to an undetectable 
viral load. Finally, in December 2010, she gave birth 
to a healthy boy; her pVL<50, and peripheral CD4 
count was 482/ml.
DISCUSSION
To the best of our knowledge, this is the first report 
of primary resistance caused by the Q151M complex. 
The infection was caused by HIV-1 subtype G. This 
case is characterized by its prolonged persistence of 
transmitted multi-drug resistance mutations, which 
lasted for seven years, namely RT mutations Q151M, 
K65R and Y181C.
Q151M,  an  NRTI  resistance  mutation,  causes 
intermediate-to-high  level  resistance  to  zidovu-
dine (AZT), didanosine (ddI), stavudine (d4T) and 
abacavir (ABC) and low-level resistance to tenofovir 
(TDF). With changes at the associated RT positions 
75, 77, and 116, Q151M confers high-level resistance 
to  zidovudine  (AZT),  didanosine  (ddI),  stavudine 
(d4T) and abacavir (ABC), intermediate resistance 
to tenofovir (TDF), and low-level resistance to lami-
vudine (3TC) and emtricitabine (FTC). K65R is also 
an NRTI resistance mutation that causes intermedi-
ate resistance to abacavir (ABC), didanosine (ddI), 
lamivudine (3TC) and emtricitabine (FTC) and low-
level resistance to stavudine (d4T). the single NNRTI 
resistance mutation that appeared in our patient was 
Y181C. This drug resistant mutation causes high-lev-
el resistance to nevirapine (NVP) and intermediate-
level resistance to efavirenz (EFV), etravirine (ETR) 
and rilpivirine (RPV). 
Drug resistance-associated mutations are classi-
fied into two classes based on their features. Primary 
mutations are responsible for drug susceptibility re-
duction regardless of the reduced replicative capac-
ity of the virus, while secondary mutations increase 
viral fitness with almost no effect on drug resistance 
(Devereux et al., 2001). It is known that TDR muta-
tions may persist for prolonged periods of time and 
may pose an important hindrance to the overall suc-
cess of antiretroviral therapy. Factors that determine 
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the number and type of these mutations and their 
impact on viral fitness (García-Lerma et al., 2004). 
The differing duration and scope of persistence 
of transmitted HIV-1 drug-resistance mutations in 
the absence of therapy has been described. Here we 
describe the case of a seven year prolonged persist-
ence of resistance mutations, caused by the Q151M 
complex. Other studies have shown the persistence of 
other mutations for over two years, without antiret-
roviral therapy (Delaugerre et al., 2004). Phylogenet-
ic analysis of several thousands of HIV-1 sequences 
containing drug-resistance mutations, revealed five 
different clusters in the United Kingdom (UK), orig-
inating from both drug-naïve and drug-treated pa-
tients (Hué et al., 2008). Detailed analysis of these 
clusters uncovered their persistence for up to eight 
years (Hué et al., 2008). Mathematical modeling al-
lowed the estimation of the average duration of TDR 
persistence, showing that, on average, 4.1 years are 
required for a complete reversion of drug resistance 
mutation (Little et al., 2008). 
Fig. 1. Results of periodical genotypic resistance testing. The white arrow denotes the transmission event. Black arrows denote time of 
genotypic resistance testing and mutations found in genes for reverse transcriptase (RT) (Q151M, K65R, Y181C) and protease (PR) 
(K20I, M36L, V82I, I93L) (the first letter denotes the amino acid in wild type strain, the number relates to the codon position, the second 
letter denotes the mutated amino acid). The patient’s bars filled in blue indicate an on therapy status, with the therapy history (abacavir 
(ABC), lamivudine (3TC), stavudine (d4T), didanosine (ddI), lopinavir/ritonavir (LPN/RTN), saquinavir (SQV)). Patient A-recipient, 
patient B-source.PRIMARY HIV-1 RESISTANCE – PERSISTENCE OF TRANSMITTED DRUG RESISTANCE MUTATIONS 1305
A  possible  explanation  for  the  persistence  of 
primary resistance mutations may be the long-term 
process of reversion to wild type. Namely, the mech-
anisms that allow this are the genetic reversion of re-
sistance mutation and viral recombination. Further-
more, the number of resistance-associated mutations 
is in correlation with the required period of time for 
their complete reversion (Delaugerre et al., 2004). 
Moreover, the patient in our study infected with a 
resistant HIV-1 strain had a relatively high number 
of CD4 cells and a low viral load. This may be the 
result of the low replicative capacity of the resistant 
virus (Brenner et al., 2002; Grant et al., 2002; Chaix 
et al., 2003). 
The action mechanism of the Q151M complex is 
based on the modification of the dNTP biding site, 
decreasing the catalytic rate constant of incorpora-
tion  of  the  analogue  into  DNA  (Menéndez-Arias, 
2008;  Hachiya  et  al.,  2011).  These  mutations  lead 
to  intermediate-to-high  level  resistance  to  multi-
ple NRTIs. First studies have revealed that Q151M 
Table 1. Specific primers used for detection 1500nt of pol region
PRIMER SEQUENCE (5’→3’)
HIV_AV159 GGGGTTAAATAAAATAGTAAG
HIV_AV192 AATTGTTTTACATCATTAGTGTG
HIV_AV190 GCTACACTAGAAGAAATGATGAC
HIV_AV191 CTTGATAAATTTGATATGTCCATTG
HIV_AV75 TGTACTGAGAGACAGGCTAATTTTTTAGGG
HIV_RVP3 GGCAAATACTGGAGTATTGTATGG
HIV_AV22 CACCTGTCAACATAAT
HIV_AV44 TACTAGGTATGGTAAATGCAGT
HIV_AV36 CAGTACTGGATGTGGGTGATG
Table 2. List of transmitted drug-associated mutations, as interpreted by the Stanford HIV database algorithm.
PI Major Resistance 
Mutations
None
PI Minor Resistance 
Mutations
None
PI Other Mutations I13V, K14R, K20I, M36Qi, R41K, I64L, C67E, H69K, V82I, L89M, I93L
NRTI Resistance 
Mutations
K65R, Q151M
NNRTI Resistance 
Mutations
Y181C
RT Other Mutations
V35T,V60I, S68G, K104R, K122E, D123S, K173T, Q174K, D177E, I178M, T200A, Q207A, R211K, 
V245Q, E248D, D250E, A272S, T286A, E291D, V292I, I293V, K311R, E312N, D324E1306 VALENTINA NIKOLIĆ ET AL.
complex mutations have the same replication fitness 
as the wild type of HIV-1 (Maeda et al., 1998). Fur-
ther investigation has revealed that a single Q151M 
mutation and Q151M complex have better fitness 
compared to a wild-type strain (Dykes and Demeter, 
2007). These results may point to the cause of the 
slow- and long-term reversion of Q151M complex 
mutations. The emergence of the Q151M complex 
requires the development of two intermediate mu-
tations, Q151L and Q151K. These mutations have 
significant lower replication fitness compared with 
the wild type, creating a high genetic barrier for de-
veloping Q151M complex (Kosalaraksa et al., 1999; 
García-Lerma et al., 2000).  
New reports indicate the existence of three evo-
lutionary pathways of viral evolution after the trans-
mission of drug-resistant HIV-1 to a new host. The 
first pathway is explained by a complete reversion 
of the major drug-resistant mutations to wild type, 
which is caused by the lower replicative capacity of 
strains with mutations compared to the wild type. 
The  second  mechanism  proposes  the  appearance 
of atypical variants with a higher replicative capac-
ity than transmitted drug-resistant forms. The last 
evolutionary pathway is explained by the persistence 
of transmitted drug-resistant viruses (Pingen et al., 
2011). The evolutionary pathway of the HIV-1 strain 
described here, after transmission has led to long-
term  persistence  of  RT  mutations.  The  proposed 
mechanism that allows the maintenance of primary 
resistance assumes that the replicative capacity of a 
transmitted drug-resistant strain is higher compared 
to a wild-type strain.
The first antiretroviral drug approved by the Food 
and  Drug  Administration  (FDA),  azidothymidine 
(AZT), belongs to the NRTI drug class (Whitcomb 
et al., 2003). Long-term use of these drugs represents 
one of the major causes of them being the most com-
mon TDRs. Broad cross-resistance among all NRTI 
drugs adds to the clinical relevance of these primary 
mutations. Q151M, as a thymidine analog mutation, 
has been found to be associated with multidrug re-
sistance mutations in the reverse transcriptase gene 
(Shafer et al., 1994; Schmit et al., 1996). Nevertheless, 
this complex of mutations does not have high rate of 
cross-resistance and is seen rather rarely (Van Vaer-
enbergh et al., 2000; Masquelier et al., 2001).
The highest risk for mother-to-child transmis-
sion is in the third trimester of pregnancy and dur-
ing delivery (Delaugerre et al., 2009); therefore, the 
third trimester of pregnancy is an indication for the 
initiation of ARV therapy. However, reports reveal 
that drug resistance was detected in 20% of infants, if 
they become infected (Delaugerre et al., 2009). This 
resistance is a consequence of either mother-to-child 
transmission or an infant’s exposure of ARV therapy 
immediately after birth.
Assessment of the primary resistance in non-B 
subtypes is very difficult because of limited sources. 
The baseline resistance of non-B infections increased 
from 2.0% in 1996-1998, to 3.0% in 1999-2000 and 
to 8.2% in 2000-2001 (Wensing et al., 2005). These 
figures match the increased number of patients in-
fected with non-B subtype who are at present being 
undertaking therapy. The problem of primary resist-
ance of B-subtype was apparent a few years before 
its appearance in non-B subtypes. This discrepancy 
is  probably  due  to  the  different  distribution  of  B 
and non-B subtypes. The predominant subtype in 
Western Europe and the United States is B, while in 
Africa, Asia and Eastern Europe widespread non-
B subtypes exist. The higher prevalence of TDR in 
Western Europe and the United States compared to 
other regions is a consequence of the long history 
of antiretroviral therapy use in developed countries 
(Chan and Kantor, 2009).
Herein we report a unique case of persistence of 
transmitted  RT  Q151M  complex  mutations  along 
with other important resistance mutations in a sub-
type G-infected patient during a seven-year period. 
This case confirms the necessity of resistance geno-
typing in both primary and chronic infections, as 
well as in pregnancy, in order to avoid HAART fail-
ure.
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